Literature DB >> 2847316

HIV-infected cells are killed by rCD4-ricin A chain.

M A Till1, V Ghetie, T Gregory, E J Patzer, J P Porter, J W Uhr, D J Capon, E S Vitetta.   

Abstract

The gp120 envelope glycoprotein of the human immunodeficiency virus (HIV), which is expressed on the surface of many HIV-infected cells, binds to the cell surface molecule CD4. Soluble derivatives of recombinant CD4 (rCD4) that bind gp120 with high affinity are attractive vehicles for targeting a cytotoxic reagent to HIV-infected cells. Soluble rCD4 was conjugated to the active subunit of the toxin ricin. This conjugate killed HIV-infected H9 cells but was 1/1000 as toxic to uninfected H9 cells (which do not express gp120) and was not toxic to Daudi cells (which express major histocompatibility class II antigens, the putative natural ligand for cell surface CD4). Specific killing of infected cells can be blocked by rgp120, rCD4, or a monoclonal antibody to the gp120 binding site on CD4.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847316     DOI: 10.1126/science.2847316

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  31 in total

1.  Infectious enveloped RNA virus antigenic chimeras.

Authors:  S D London; A L Schmaljohn; J M Dalrymple; C M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

2.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Authors:  Antonella Castagna; Priscilla Biswas; Alberto Beretta; Adriano Lazzarin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

4.  A CD 4: immunoglobulin fusion protein with antiviral effects against HIV.

Authors:  J P Gregersen; S Mehdi; H Gelderblom; G Zettlmeissl
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

5.  Immunization of simian immunodeficiency virus-infected rhesus monkeys with soluble human CD4 elicits an antiviral response.

Authors:  M Watanabe; C G Levine; L Shen; R A Fisher; N L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

6.  Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis.

Authors:  A Ashkenazi; L G Presta; S A Marsters; T R Camerato; K A Rosenthal; B M Fendly; D J Capon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 7.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

8.  RNase inhibition of human immunodeficiency virus infection of H9 cells.

Authors:  R J Youle; Y N Wu; S M Mikulski; K Shogen; R S Hamilton; D Newton; G D'Alessio; M Gravell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

9.  Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Authors:  Edward A Berger; Ira Pastan
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

10.  Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus.

Authors:  K D Bell; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.